Infusion of cytomegalovirus specific cytotoxic T lymphocytes from a sero-negative donor can facilitate resolution of infection and immune reconstitution.

Department of Pediatrics, Blood and Marrow Transplant Program, University of California, San Francisco, CA.
The Pediatric Infectious Disease Journal (Impact Factor: 3.14). 12/2008; 28(1):65-7. DOI: 10.1097/INF.0b013e318182026f
Source: PubMed

ABSTRACT We report a stem cell transplant patient with a therapy-refractory cytomegalovirus (CMV) infection who received CMV-specific T cells from his sero-negative stem cell donor. This donor received the Towne strain CMV vaccine, and T cells were expanded using monocytes pulsed with pp65 overlapping peptides. CMV DNA decreased after the CTL infusion, and CMV-specific cytotoxicity increased. This strategy could be implemented in similar situations or with persistent viremia post-transplant.

  • Value in Health 05/2005; 8(3):387-387. DOI:10.1016/S1098-3015(10)63044-6 · 2.89 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Passive immunization against CMV is desirable to minimize or perhaps eliminate complications related to CMV disease. In allogeneic hematopoietic cell transplantation (allo-HCT), the major challenge facing a successful anti-CMV vaccine is inducing immunity in an immunocompromised host. To date, only one CMV vaccine, ASP0113, has been evaluated in a randomized, placebo-controlled Phase II study. ASP0113 is a bivalent product containing two plasmids that encode CMV glycoprotein B and tegument phosphoprotein 65, respectively. Although there was no significant difference in rate of initiation of anti-CMV therapy, rates of CMV viremia were lower in the ASP0113 group when measured by a central laboratory. Also, time-to-first episode of viremia was longer in subjects receiving ASP0113. These findings paved the way for an ongoing placebo-controlled Phase III study aiming at enrolling 500 subjects. Results of this Phase III trial, especially if it meets clinically meaningful endpoints, will ultimately determine the role of anti-CMV vaccine strategies in allo-HCT.
    Expert Review of Vaccines 12/2014; 14(3):1-10. DOI:10.1586/14760584.2015.989990 · 4.22 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: T-cell response to cytomegalovirus (CMV) is essential in the control of viral replication. Quantification of functional CD4+ and CD8+ T lymphocytes against certain CMV-antigen specificities through flow cytometry, ELISPOT or the QuantiFERON®-CMV kit allows fairly accurate estimation of the risk of active infection and CMV disease in solid organ transplantation (SOT). Combined virological and immunological monitoring of CMV infection could allow antiviral treatments to be individually tailored and optimized in SOT, although clinical experience is currently lacking. The adoptive transfer of CMV-specific T cells before selection with multimer HLA peptides or after activation and expansion ex vivo could be an effective therapeutic alternative in the management of active infection or organic CMV disease refractory to antiviral therapy. Several CMV vaccines have been developed, which have been shown to be safe and immunogenic in preclinical and Phase I clinical trials. However, to date, none of these vaccines has been evaluated in Phase III clinical trials and consequently none has been approved for clinical use.
    Enfermedades Infecciosas y Microbiología Clínica 12/2011; 29:28–32. DOI:10.1016/S0213-005X(11)70054-4 · 1.88 Impact Factor